Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 21
19
Diseases
1,872
Unique genes
0.057
Avg. similarity score
Breast neoplasms
Most-connected disease (9 links)
Disease
Searched: Hypotrichosis and recurrent skin vesicles
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Hypotrichosis and recurrent skin vesicles
Breast neoplasms
Lung neoplasms
Stomach neoplasms
Liver neoplasms
Urinary bladder neoplasms
Non-small-cell lung carcinoma
Prostatic neoplasms
Neuroblastoma
Carcinoma
Mesothelioma
Pulmonary agenesis
Uterine neoplasms
Cerebellar ataxia, brain abnormalities, and cardiac conduction defects
Colobomatous macrophthalmia microcornea syndrome
Diffuse lymphatic malformation
Intellectual developmental disorder seizures polymicrogyria
Isobutyryl-coa dehydrogenase deficiency
Retinitis pigmentosa, hearing loss, premature aging, short stature, facial dysmorphism syndrome
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Breast neoplasms | 9 | 9 | 529 |
| Lung neoplasms | 8 | 8 | 254 |
| Stomach neoplasms | 7 | 7 | 306 |
| Liver neoplasms | 6 | 6 | 152 |
| Urinary bladder neoplasms | 6 | 6 | 142 |
| Non-small-cell lung carcinoma | 5 | 5 | 137 |
| Prostatic neoplasms | 5 | 5 | 627 |
| Neuroblastoma | 4 | 4 | 151 |
| Carcinoma | 3 | 3 | 165 |
| Mesothelioma | 2 | 2 | 145 |
| Pulmonary agenesis | 2 | 2 | 1 |
| Uterine neoplasms | 2 | 2 | 38 |
| Cerebellar ataxia, brain abnormalities, and cardiac conduction defects | 1 | 1 | 1 |
| Colobomatous macrophthalmia microcornea syndrome | 1 | 1 | 1 |
| Diffuse lymphatic malformation | 1 | 1 | 1 |
| Hypotrichosis and recurrent skin vesicles | 1 | 1 | 1 |
| Intellectual developmental disorder seizures polymicrogyria | 1 | 1 | 1 |
| Isobutyryl-coa dehydrogenase deficiency | 1 | 1 | 1 |
| Retinitis pigmentosa, hearing loss, premature aging, short stature, facial dysmorphism syndrome | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases ‐ top 100 shown, download for all)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| KRAS | 10 / 19 | Breast neoplasms, Carcinoma, Liver neoplasms, Lung neoplasms and 6 more |
| TP53 | 10 / 19 | Breast neoplasms, Carcinoma, Liver neoplasms, Lung neoplasms and 6 more |
| MYC | 9 / 19 | Carcinoma, Liver neoplasms, Lung neoplasms, Neuroblastoma and 5 more |
| STAT3 | 9 / 19 | Breast neoplasms, Carcinoma, Liver neoplasms, Lung neoplasms and 5 more |
| BAP1 | 8 / 19 | Breast neoplasms, Liver neoplasms, Lung neoplasms, Mesothelioma and 4 more |
| CCND1 | 8 / 19 | Breast neoplasms, Carcinoma, Liver neoplasms, Lung neoplasms and 4 more |
| CDKN2A | 8 / 19 | Breast neoplasms, Liver neoplasms, Lung neoplasms, Mesothelioma and 4 more |
| EGFR | 8 / 19 | Breast neoplasms, Carcinoma, Lung neoplasms, Mesothelioma and 4 more |
| ESR1 | 8 / 19 | Breast neoplasms, Carcinoma, Liver neoplasms, Lung neoplasms and 4 more |
| FHIT | 8 / 19 | Carcinoma, Liver neoplasms, Lung neoplasms, Mesothelioma and 4 more |
| HRAS | 8 / 19 | Breast neoplasms, Carcinoma, Liver neoplasms, Lung neoplasms and 4 more |
| CDKN1B | 7 / 19 | Breast neoplasms, Liver neoplasms, Lung neoplasms, Mesothelioma and 3 more |
| GSTP1 | 7 / 19 | Breast neoplasms, Carcinoma, Lung neoplasms, Non-small-cell lung carcinoma and 3 more |
| MET | 7 / 19 | Carcinoma, Lung neoplasms, Mesothelioma, Neuroblastoma and 3 more |
| SOD2 | 7 / 19 | Breast neoplasms, Carcinoma, Mesothelioma, Non-small-cell lung carcinoma and 3 more |
| TERT | 7 / 19 | Breast neoplasms, Liver neoplasms, Lung neoplasms, Neuroblastoma and 3 more |
| APC | 6 / 19 | Liver neoplasms, Lung neoplasms, Mesothelioma, Non-small-cell lung carcinoma and 2 more |
| BIRC5 | 6 / 19 | Breast neoplasms, Lung neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms and 2 more |
| CDH1 | 6 / 19 | Breast neoplasms, Carcinoma, Mesothelioma, Prostatic neoplasms and 2 more |
| CDKN1A | 6 / 19 | Liver neoplasms, Lung neoplasms, Mesothelioma, Prostatic neoplasms and 2 more |
| CSF3 | 6 / 19 | Breast neoplasms, Carcinoma, Liver neoplasms, Non-small-cell lung carcinoma and 2 more |
| CTNNB1 | 6 / 19 | Breast neoplasms, Liver neoplasms, Lung neoplasms, Mesothelioma and 2 more |
| CXCL8 | 6 / 19 | Breast neoplasms, Mesothelioma, Non-small-cell lung carcinoma, Prostatic neoplasms and 2 more |
| MTHFR | 6 / 19 | Breast neoplasms, Lung neoplasms, Prostatic neoplasms, Stomach neoplasms and 2 more |
| MTOR | 6 / 19 | Breast neoplasms, Mesothelioma, Non-small-cell lung carcinoma, Prostatic neoplasms and 2 more |
| RAF1 | 6 / 19 | Breast neoplasms, Liver neoplasms, Lung neoplasms, Mesothelioma and 2 more |
| TNF | 6 / 19 | Breast neoplasms, Liver neoplasms, Lung neoplasms, Neuroblastoma and 2 more |
| ARID1A | 5 / 19 | Breast neoplasms, Neuroblastoma, Prostatic neoplasms, Stomach neoplasms and 1 more |
| BCL2 | 5 / 19 | Breast neoplasms, Carcinoma, Mesothelioma, Prostatic neoplasms and 1 more |
| CCNH | 5 / 19 | Breast neoplasms, Carcinoma, Liver neoplasms, Non-small-cell lung carcinoma and 1 more |
| CHEK2 | 5 / 19 | Breast neoplasms, Lung neoplasms, Neuroblastoma, Prostatic neoplasms and 1 more |
| ERBB2 | 5 / 19 | Breast neoplasms, Lung neoplasms, Prostatic neoplasms, Stomach neoplasms and 1 more |
| GSTM1 | 5 / 19 | Liver neoplasms, Lung neoplasms, Mesothelioma, Prostatic neoplasms and 1 more |
| HIF1A | 5 / 19 | Breast neoplasms, Carcinoma, Non-small-cell lung carcinoma, Prostatic neoplasms and 1 more |
| HMOX1 | 5 / 19 | Breast neoplasms, Liver neoplasms, Lung neoplasms, Prostatic neoplasms and 1 more |
| IL6 | 5 / 19 | Breast neoplasms, Lung neoplasms, Mesothelioma, Prostatic neoplasms and 1 more |
| MMP9 | 5 / 19 | Breast neoplasms, Neuroblastoma, Non-small-cell lung carcinoma, Prostatic neoplasms and 1 more |
| NAT2 | 5 / 19 | Breast neoplasms, Liver neoplasms, Mesothelioma, Prostatic neoplasms and 1 more |
| NFE2L2 | 5 / 19 | Breast neoplasms, Liver neoplasms, Lung neoplasms, Non-small-cell lung carcinoma and 1 more |
| PTGS2 | 5 / 19 | Breast neoplasms, Carcinoma, Prostatic neoplasms, Stomach neoplasms and 1 more |
| RB1 | 5 / 19 | Breast neoplasms, Carcinoma, Non-small-cell lung carcinoma, Prostatic neoplasms and 1 more |
| ABCB1 | 4 / 19 | Breast neoplasms, Carcinoma, Neuroblastoma, Non-small-cell lung carcinoma |
| AHR | 4 / 19 | Breast neoplasms, Liver neoplasms, Prostatic neoplasms, Stomach neoplasms |
| AKT1 | 4 / 19 | Breast neoplasms, Lung neoplasms, Prostatic neoplasms, Urinary bladder neoplasms |
| ATM | 4 / 19 | Breast neoplasms, Prostatic neoplasms, Stomach neoplasms, Urinary bladder neoplasms |
| ATP7B | 4 / 19 | Breast neoplasms, Carcinoma, Liver neoplasms, Prostatic neoplasms |
| CASP8 | 4 / 19 | Breast neoplasms, Lung neoplasms, Stomach neoplasms, Uterine neoplasms |
| CAT | 4 / 19 | Breast neoplasms, Mesothelioma, Non-small-cell lung carcinoma, Urinary bladder neoplasms |
| CAV1 | 4 / 19 | Breast neoplasms, Lung neoplasms, Prostatic neoplasms, Stomach neoplasms |
| CLPTM1L | 4 / 19 | Lung neoplasms, Prostatic neoplasms, Urinary bladder neoplasms, Uterine neoplasms |
| CYP2E1 | 4 / 19 | Liver neoplasms, Lung neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms |
| DNMT1 | 4 / 19 | Breast neoplasms, Carcinoma, Prostatic neoplasms, Stomach neoplasms |
| DNMT3B | 4 / 19 | Breast neoplasms, Carcinoma, Prostatic neoplasms, Stomach neoplasms |
| EFEMP1 | 4 / 19 | Breast neoplasms, Carcinoma, Lung neoplasms, Mesothelioma |
| ENO1 | 4 / 19 | Breast neoplasms, Carcinoma, Non-small-cell lung carcinoma, Stomach neoplasms |
| EPHX1 | 4 / 19 | Carcinoma, Lung neoplasms, Mesothelioma, Prostatic neoplasms |
| ERCC1 | 4 / 19 | Lung neoplasms, Non-small-cell lung carcinoma, Stomach neoplasms, Uterine neoplasms |
| ESR2 | 4 / 19 | Breast neoplasms, Carcinoma, Prostatic neoplasms, Urinary bladder neoplasms |
| HES1 | 4 / 19 | Breast neoplasms, Lung neoplasms, Non-small-cell lung carcinoma, Uterine neoplasms |
| IL10 | 4 / 19 | Breast neoplasms, Lung neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms |
| IL1B | 4 / 19 | Breast neoplasms, Lung neoplasms, Neuroblastoma, Stomach neoplasms |
| IL2 | 4 / 19 | Liver neoplasms, Lung neoplasms, Prostatic neoplasms, Urinary bladder neoplasms |
| JUN | 4 / 19 | Breast neoplasms, Liver neoplasms, Lung neoplasms, Stomach neoplasms |
| MACIR | 4 / 19 | Breast neoplasms, Liver neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms |
| MDM2 | 4 / 19 | Breast neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms, Stomach neoplasms |
| MIF | 4 / 19 | Breast neoplasms, Carcinoma, Mesothelioma, Prostatic neoplasms |
| NCOR1 | 4 / 19 | Breast neoplasms, Liver neoplasms, Prostatic neoplasms, Urinary bladder neoplasms |
| NDRG1 | 4 / 19 | Breast neoplasms, Liver neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms |
| NOTCH2 | 4 / 19 | Breast neoplasms, Lung neoplasms, Stomach neoplasms, Uterine neoplasms |
| NQO1 | 4 / 19 | Breast neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms, Urinary bladder neoplasms |
| PHGDH | 4 / 19 | Breast neoplasms, Liver neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms |
| PIK3CA | 4 / 19 | Breast neoplasms, Lung neoplasms, Prostatic neoplasms, Stomach neoplasms |
| PTEN | 4 / 19 | Breast neoplasms, Carcinoma, Lung neoplasms, Prostatic neoplasms |
| PYCARD | 4 / 19 | Lung neoplasms, Mesothelioma, Non-small-cell lung carcinoma, Stomach neoplasms |
| RARB | 4 / 19 | Breast neoplasms, Lung neoplasms, Stomach neoplasms, Uterine neoplasms |
| RASSF1 | 4 / 19 | Lung neoplasms, Mesothelioma, Non-small-cell lung carcinoma, Urinary bladder neoplasms |
| TGFA | 4 / 19 | Liver neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms, Stomach neoplasms |
| TNFSF10 | 4 / 19 | Breast neoplasms, Liver neoplasms, Neuroblastoma, Prostatic neoplasms |
| TYMS | 4 / 19 | Breast neoplasms, Lung neoplasms, Prostatic neoplasms, Stomach neoplasms |
| VIM | 4 / 19 | Breast neoplasms, Carcinoma, Mesothelioma, Prostatic neoplasms |
| ACE | 3 / 19 | Lung neoplasms, Prostatic neoplasms, Stomach neoplasms |
| ACHE | 3 / 19 | Breast neoplasms, Prostatic neoplasms, Urinary bladder neoplasms |
| ALK | 3 / 19 | Breast neoplasms, Neuroblastoma, Non-small-cell lung carcinoma |
| ANXA2 | 3 / 19 | Liver neoplasms, Lung neoplasms, Mesothelioma |
| ANXA4 | 3 / 19 | Carcinoma, Liver neoplasms, Prostatic neoplasms |
| APOA1 | 3 / 19 | Lung neoplasms, Mesothelioma, Stomach neoplasms |
| APOBEC3B | 3 / 19 | Breast neoplasms, Urinary bladder neoplasms, Uterine neoplasms |
| AR | 3 / 19 | Breast neoplasms, Lung neoplasms, Prostatic neoplasms |
| AREG | 3 / 19 | Breast neoplasms, Non-small-cell lung carcinoma, Stomach neoplasms |
| AURKA | 3 / 19 | Breast neoplasms, Neuroblastoma, Prostatic neoplasms |
| BCL2L1 | 3 / 19 | Carcinoma, Lung neoplasms, Stomach neoplasms |
| BIRC2 | 3 / 19 | Breast neoplasms, Neuroblastoma, Stomach neoplasms |
| BRAF | 3 / 19 | Liver neoplasms, Lung neoplasms, Prostatic neoplasms |
| BRCA1 | 3 / 19 | Breast neoplasms, Carcinoma, Prostatic neoplasms |
| BRCA2 | 3 / 19 | Breast neoplasms, Lung neoplasms, Prostatic neoplasms |
| CDH13 | 3 / 19 | Lung neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms |
| CDK4 | 3 / 19 | Breast neoplasms , Carcinoma, Stomach neoplasms |
| CHD6 | 3 / 19 | Neuroblastoma, Prostatic neoplasms, Urinary bladder neoplasms |
| CSF2 | 3 / 19 | Breast neoplasms, Carcinoma, Liver neoplasms |
| CST6 | 3 / 19 | Breast neoplasms, Non-small-cell lung carcinoma, Prostatic neoplasms |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Pathways in cancer | KEGG | 224 / 533 | 2.7× | 2.07e-51 | 3.63e-47 ✓ sig. |
| Prostate cancer | KEGG | 71 / 98 | 4.7× | 1.48e-36 | 6.30e-33 ✓ sig. |
| Endocrine resistance | KEGG | 63 / 99 | 4.1× | 1.63e-27 | 3.55e-24 ✓ sig. |
| Breast cancer | KEGG | 79 / 148 | 3.4× | 7.44e-27 | 1.45e-23 ✓ sig. |
| PI3K-Akt signaling pathway | KEGG | 138 / 361 | 2.5× | 1.25e-26 | 2.38e-23 ✓ sig. |
| Non-small cell lung cancer | KEGG | 52 / 73 | 4.6× | 1.66e-26 | 3.06e-23 ✓ sig. |
| Proteoglycans in cancer | KEGG | 95 / 204 | 3.0× | 4.18e-26 | 7.36e-23 ✓ sig. |
| Bladder cancer | KEGG | 37 / 41 | 5.8× | 4.46e-26 | 7.72e-23 ✓ sig. |
| Pancreatic cancer | KEGG | 52 / 77 | 4.4× | 9.30e-25 | 1.39e-21 ✓ sig. |
| Melanoma | KEGG | 50 / 73 | 4.4× | 2.74e-24 | 4.00e-21 ✓ sig. |
| EGFR tyrosine kinase inhibitor resistance | KEGG | 52 / 80 | 4.2× | 1.44e-23 | 1.79e-20 ✓ sig. |
| Hepatocellular carcinoma | KEGG | 81 / 170 | 3.1× | 3.08e-23 | 3.66e-20 ✓ sig. |
| Gastric cancer | KEGG | 75 / 150 | 3.2× | 3.10e-23 | 3.66e-20 ✓ sig. |
| Interleukin-4 and Interleukin-13 signaling | Reactome | 61 / 108 | 3.6× | 9.74e-23 | 1.10e-19 ✓ sig. |
| Lipid and atherosclerosis | KEGG | 93 / 216 | 2.8× | 1.59e-22 | 1.77e-19 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| positive regulation of transcription by RNA polymerase II | GO:0045944 | 294 / 1,208 | 2.4× | 2.40e-51 | 5.29e-47 ✓ sig. |
| negative regulation of apoptotic process | GO:0043066 | 171 / 524 | 3.3× | 1.48e-47 | 2.49e-43 ✓ sig. |
| positive regulation of gene expression | GO:0010628 | 160 / 504 | 3.2× | 9.18e-43 | 1.14e-38 ✓ sig. |
| positive regulation of cell population proliferation | GO:0008284 | 160 / 532 | 3.0× | 1.84e-39 | 1.85e-35 ✓ sig. |
| negative regulation of transcription by RNA polymerase II | GO:0000122 | 226 / 1,002 | 2.3× | 1.21e-33 | 9.07e-30 ✓ sig. |
| apoptotic process | GO:0006915 | 183 / 747 | 2.5× | 5.65e-32 | 3.62e-28 ✓ sig. |
| positive regulation of cell migration | GO:0030335 | 100 / 292 | 3.4× | 5.49e-30 | 3.02e-26 ✓ sig. |
| negative regulation of cell population proliferation | GO:0008285 | 128 / 444 | 2.9× | 1.13e-29 | 6.03e-26 ✓ sig. |
| positive regulation of MAPK cascade | GO:0043410 | 85 / 224 | 3.8× | 2.71e-29 | 1.41e-25 ✓ sig. |
| positive regulation of DNA-templated transcription | GO:0045893 | 182 / 778 | 2.3× | 4.02e-29 | 2.03e-25 ✓ sig. |
| response to xenobiotic stimulus | GO:0009410 | 87 / 248 | 3.5× | 4.38e-27 | 1.93e-23 ✓ sig. |
| negative regulation of gene expression | GO:0010629 | 101 / 339 | 3.0× | 7.83e-25 | 2.61e-21 ✓ sig. |
| response to hypoxia | GO:0001666 | 68 / 176 | 3.9× | 3.28e-24 | 9.87e-21 ✓ sig. |
| positive regulation of apoptotic process | GO:0043065 | 97 / 326 | 3.0× | 7.59e-24 | 2.19e-20 ✓ sig. |
| cell population proliferation | GO:0008283 | 84 / 263 | 3.2× | 4.69e-23 | 1.19e-19 ✓ sig. |